| HAIR RESTORATION | PEER-REVIEW
Gilbert Amgar and Pierre Bouhanna discuss the use of microneedling along with platelet rich plasma for the treatment of androgenic alopecia
ANDROGENIC ALOPECIA
AUTOLOGOUS INPRP
JECTION IN
The use of Platelet Rich Plasma (PRP)
ABSTRACT in
cosmetic applications
well established and documented. Hair
medicine became
is now available
over the last 8 years. The two main fields of application for PRP are hair
female pattern baldness, the new hair is fine and thin (intermediate hair or miniaturised hair). Male and female baldness usually progresses in a defined pattern. The most publicised medical treatment available for
A
male pattern baldness is 5% minoxidil lotion and 2% minoxidil for female baldness. Side-effects of minoxidil are minimal but include itching, eczema, and hypertrichosis in females. For male baldness, finasteride taken orally and daily (1 mg) inhibits the 5α reductase from forming dihydrotestosterone (DHT) and may lead to decreased libido. Spironolactone (in US) appears to be a competitive inhibitor of DHT-receptor binding. Cyproterone acetate (in Europe) can effectively block increased levels of male hormones that cause hair loss in some women. A new interest in preventing baldness has been
regrowth (androgenic alopecia, alopecia areata) and surgery (to improve hair transplants). Indeed, some of the treatments that exist in this field provide quantifiable results. In this study, the authors conducted an objective evaluation of androgenic alopecia for
NDROGENIC ALOPECIA IS AN extremely common disease that affects both men and women. In normal hair loss, less than one hundred hairs fall each day and are replaced by new thick hair. In the evolution of male and
over 2 years. The study consisted of 70
patients and each case is
documented by digital parameters (hair density, diameter, ratio terminal vellus) and standard photography. Follow-up 3 months after treatment, the authors observed an increase in hair density of
19%, which reached 38% at 12 months. The authors believe it would be suitable to consolidate these results with other evaluations of the same type, carried out by other teams and gradually define the best protocols in order to maximise the results.
stimulated by cellular therapy with platelet rich plasma (PRP) injected directly into the scalp. Aiming for better tolerance, an easier process, and high
satisfaction rates, researchers and doctors have been looking for improved treatments in this field for a number of years. In this context, PRP takes a prominent place. PRP is defined as an autologous concentrated preparation of platelets and their associated growth factors in a small volume of plasma. The revitalisation qualities of the platelets are well known and have been used for 30 years in various specialties such as plastic surgery, dermatology, rheumatology, and dentistry. The first publication on this subject goes back to 19751
and publications of its use on
the scalp date back to 2007. PRP eliminates concerns for disease transmission and minimises possible side-effects. The challenge remains to evaluate the results with objective parameters2
.
Epidemiology The prevalence and severity of pattern hair loss increases with age and the greatest incidence is in Caucasian people. In general, 30% of Caucasian males are affected
KEYWORDS PRP, Platelets Rich Plasma, androgenic alopecia, phototrichogram, Tropocells® kit
prime-journal.com | March 2015 ❚ 25
GILBERT AMGAR, MD, is Aesthetic Practitioner, France; and PIERRE BOUHANNA, is Dermatologist and Expert in Hair Surgery, Paris, France
email:
gilbert.amgar@
orange.fr
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96